SA cardiovascular laboratories mining diverse, yet relevant research topics by Woodiwiss, Angela & Norton, Gavin
SA cardiovascular laboratories 
mining diverse, yet relevant 
research topics
138
EDITORIAL
This issue of SA Heart reports on some ongoing work performed in South Africa that engages with 
more fundamental issues of the mechanisms of cardiovascular disease. This special edition of the 
journal highlights some of the high quality, internationally competitive, clinically relevant, basic cardio-
vascular science presently being undertaken by a number of groups around the country in this regard. 
Although the topics covered in the present issue are diverse, all have an important clinical context and 
in this editorial we will attempt to describe this context.
The signifi cance of nitric oxide (NO) in cardiovascular disease, including coronary artery disease, has 
been recognised for decades. More recently, the role of NO in arterial stiffness(1) and hence systemic 
hypertension, myocardial remodelling and heart failure(2) has been underscored. From a therapeutic 
perspective, however, although many drugs (and lifestyle changes) may infl uence NO, with respect to 
the development of interventions that specifi cally target NO, this has only really translated into the 
use of short- and long-acting nitrates in angina pectoris.(3) In this regard, the development of toler-
ance or cross-tolerance to nitrates(3) and the exquisite sensitivity of NO production to even small 
changes in mechanical factors(4) may limit these drug development programmes. Nevertheless, interest 
in targeting NO production in cardiovascular disease has retained a high profi le, including the possibility 
of gene therapy.(5) In the light of this, it may not be surprising that when requests for basic science 
contributions to the current edition of SA Heart were forwarded, three separate groups provided 
papers on the role of NO.
Based on their own and other contributions to this fi eld, on page 174 of this edition Strijdom and 
Lochner(6) have reviewed the present understanding of the role of myocardial NO on cardiac patho-
logy. Despite the evidence that supports a role for NO in mediating adverse ventricular remodel-
ling(2) and function and dysfunction,(6) the limited capacity of cardiac myocytes to produce NO has 
forced many of us to take a pragmatic view on the potential that therapeutic targeting of myocardial 
NO will produce benefi ts. Strijdom and Lochner have nevertheless provided convincing evidence that 
cardiac endothelial cells are the dominant source of NO both under normoxic conditions and in 
hypoxia.(6) Together with recent data to show that a compound that enhances endothelial NO 
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synthase expression improves function in experimental myocardial infarction,(7) the data provided by 
Strijdom and Lochner lend credibility to the hypothesis that targeting myocardial as opposed to 
coronary artery NO production is indeed a worthy pursuit in cardiac pathology.  We believe that this 
will become a ‘hot topic’ in future drug development.
There is no question as to the importance of hypertension in the generation of cardiac pathology in 
emerging communities in sub-Saharan Africa.(8) We believe that the poor management of hyper-
tension in these communities represents not only inappropriate care, but also a degree of resistance to 
drug therapy with many patients requiring multiple agents. Despite the evidence that NO may play a 
role in blood pressure control1 - and hence could be a therapeutic target of drug development 
programmes - unfortunately there is little evidence to support this notion in emerging communities. 
However, in the present edition of SA Heart, two studies(9,10) provide some evidence to support a 
role for NO in the pathogenesis of an increased blood pressure in emerging communities.
On page 148 of this edition, Candy, et al.(9) show that in hypertensives off-treatment, the NO synthase 
gene is associated with an ~7 mm Hg mean difference in ambulatory systolic blood pressure, in a 
relatively large study for one of this kind (n=503 patients with 24-hour blood pressure data off 
therapy). This is a remarkable difference considering the impact that this would have on cardiovascular 
events. These data are even more important considering the recent data from the A-HeFT Trial 
showing that this genotype is also associated with response to therapy to the isosorbide dinitrate-
hydralazine combination in African-Americans with heart failure.(11) Although on more tentative ground, 
on page 142 of this edition Naidoo, et al.(10) show a positive correlation between concentrations of 
the precursor for NO, plasma arginine, and ambulatory blood pressure in persons of African descent, 
arguing that this relationship may represent a reduced capacity for cellular uptake of arginine, a hypo-
thesis that is supported by other authors. Together, these two papers(9,10) suggest that considerably 
more work is required to evaluate the potential of stimulating NO production or its cellular targets in 
the treatment of hypertension in emerging communities in Africa.
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As underscored by Vengethasamy, et al.(12) on page 154 of this edition of SA Heart, there is increasing 
evidence that heart failure may occur in obese patients independent of alternative risk factors and 
myocardial infarction. This is of considerable importance considering the high percentage of people in 
emerging communities in South Africa who are obese. However as pointed out by the authors of this 
paper(12) the mechanisms of obesity-induced myocardial dysfunction are unclear as previous studies 
have not been able to segregate the adverse effects of blood pressure or diabetes mellitus on the 
myocardium from those effects produced by obesity per se. In their paper(12) Vengethasamy, et al. 
provide evidence to suggest that even mild obesity may promote cardiac myocyte apoptosis without 
increases in blood pressure or diabetes mellitus. This effect was nevertheless only noted in the 
presence of excessive adrenergic activation and hence these data may be of importance in obese 
patients with established heart failure where excessive adrenergic activation occurs.
Early myocardial reperfusion is critical to the successful outcome post myocardial infarction.(13) In the 
South African context however the timing of myocardial reperfusion is far from optimal - hence alterna-
tive approaches to reducing myocardial damage incurred by ischaemia/reperfusion are vital. In this 
regard, there is therefore great interest in identifying the possible molecular mimics of myocardial 
ischaemic preconditioning (protection by short periods of ischaemia and reperfusion)(13,14) which 
could be administered either before or during reperfusion to reduce myocardial ischaemia/reper-
fusion injury.(15) On page 168 of this edition of SA Heart, Somers, et al.(16) provide an important 
contribution to the expanding literature in this fi eld by excluding the potential role of the classic 
prosurvival factor Erk in both ischaemic and cytokine (low dose tumour necrosis factor-) mediated 
preconditioning. Having excluded Erk, the authors(16) are well placed to identify the key molecular 
mechanism(s) for drug discovery programmes.     
   
In large clinical studies, it has been shown that levels of apolipoprotein C-III (apoC-III) are a better 
predictor of risk for coronary artery disease (CAD) than the traditionally measured triglyceride 
levels.(17,18) Over-expression of apoC-III causes delayed clearance of triglyceride-rich lipoproteins from 
the plasma resulting in hypertriglyceridemia.(19) In this regard, two promoter region polymorphisms 
(T-455C and C-482T) in the gene encoding apoC-III may result in increased synthesis of apoC-III 
and thus contribute to hypertriglyceridaemia.(20) However literature on the possible association 
between hypertriglyceridaemia and these two apoC-III polymorphisms is inconsistent (cited by Naran, 
et al.(21)). On page 162 of this edition Naran, et al.(21) provide the fi rst data on these two apoC-III 
polymorphisms collected in various South African population groups. The study of Naran, et al.(21) 
suggests that either of these polymorphisms are not associated with increased triglyceride levels in 
South African populations. Naran, et al.(21) are careful to acknowledge that their study is limited by a 
small sample size. Possible reasons for the discrepancies in the literature include differences in body 
mass index (which is a major determinant of triglyceride levels) and the clinical characteristics of the 
populations studied (presence of CAD, metabolic syndrome or type II diabetes mellitus). 
In summary, we are of the belief that this edition of SA Heart showcases just some of the cardiovas-
cular laboratories in South Africa that are engaged in internationally competitive, clinically relevant 
basic research. We hope that this edition stimulates the much needed further research in these topics 
and promotes the view that SA Heart represents the interests of an audience who value and engage 
in both nationally and internationally relevant and competitive research.
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